Anti-Human IL-5 Reference Antibody (Mepolizumab, RUO) (HY218026)

Name: Anti-Human IL-5 Reference Antibody (Mepolizumab, RUO)
Brand: abinScience
SKU: HY218026
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HY218026
Descripción	Mepolizumab (HY218026) is a research-grade recombinant antibody targeting IL5. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1-kappa
Sistema de expresión	Mammalian cells
Aplicaciones probadas	WB
Objetivo	IL5, B-cell differentiation factor I, IL-5, T-cell replacing factor, TRF, Eosinophil differentiation factor, Interleukin-5
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P05113
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	SB-240563, 196078-29-2
Fondo	Interleukin-5 (IL5) is a ~15 kDa protein. Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation. Mechanistically, exerts its biological effects through a receptor composed of IL5RA subunit and the cytokine receptor common subunit beta/CSF2RB. Binding to the receptor leads to activation of various kinases including LYN, SYK and JAK2 and thereby propagates signals through the RAS-MAPK and JAK-STAT5 pathways respectively. IL5 is the therapeutic target of mepolizumab (Nucala). 1. Clutterbuck, EJ. et al. (1989) Blood 73, 1504-12. PMID: 2653458 2. Ochiai, K. et al. (1997) Clinical and experimental immunology 107, 198-204. PMID: 9010276 3. Tavernier, J. et al. (1992) Proceedings of the National Academy of Sciences of the United States of America 89, 7041-5. PMID: 1495999 4. Kusano, S. et al. (2012) Protein science : a publication of the Protein Society 21, 850-64. PMID: 22528658 5. Alam, R. et al. (1995) International archives of allergy and immunology 107, 226-7. PMID: 7613138
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)

Imágenes

SDS-PAGE

SDS-PAGE for Research Grade Mepolizumab.
Bioactivity

SEC-HPLC detection for Research Grade Mepolizumab.
Western blot

Western blot analysis was performed using anti-IL5 monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant human IL5 (Catalog No: HY218012), 50ng
Lane 2: recombinant human IL5 (Catalog No: HY218012), 30ng
Lane 3: recombinant human IL5 (Catalog No: HY218012), 20ng